Despite a couple of notable ‘firsts’ for European public biotech financing, biotech’s COVID-19 bubble may be about to burst. Virus fears pushed both private and public investors toward biotech, but vaccination successes have changed the sentiment. Now, it seems there are simply too many biotech companies, especially in Europe.
CAR-T cells against cancer
BackgroundCancer immunotherapy exploits the body’s own immune system to fight against cancer. CAR-T cell therapy is one of the breakthrough approaches that involves re-engineering a patient’s own
T cells to recognize and eradicate cancer.
Building on the advances made during the pandemic
OpinionThe pharmaceutical industry has made significant advances in collaboration over the past two years, and I have seen many examples amongst Pistoia Alliance members of the power of cooperative working. It is imperative that the industry continues to build on these successes.
Sanofi acquires therapeutic acne vaccine
Latest NewsSanofi is strengthening its vaccine business by acquiring an Austrian company. The French pharma group is taking over skin disease specialist Origrimm Biotechnology.
Deutsche Börse publishes BIOTECH Insight
BackgroundEarly December, Deutsche Börse has started BIOTECH Insight, a new information service on the German biotech industry.
US-Greek Venture gets €32m cash injection
Latest NewsUS cell & gene therapy manufacturer Orgenesis Inc. announced that its joint venture with Theracell Advanced Biotechnology SA has received €32m in funding by Enterprise Greece.
The Digital Campus
BackgroundBuilding on a relentless commitment to customer service and innovation, Beckman Coulter Life Sciences debuts a powerful new interactive customer resource with the launch of its Digital Campus. The 3D platform provides greater access to the company’s resources regardless of physical location and allows users to control their experience including the chance to get up close and personal with products and experts.
Vaccines burst 2021 biotech bubble
OpinionDespite a couple of notable ‘firsts’ for European public biotech financing, biotech’s COVID-19 bubble may be about to burst. Virus fears pushed both private and public investors toward biotech, but vaccination successes have changed the sentiment. Now, it seems there are simply too many biotech companies, especially in Europe.
Immunovia in search of a new CEO
AppointmentsLund-based Immunovia will need a new CEO, because Patrik Dahlen wants to leave the diagnostics company for personal reasons.
Early-stage ventures fighting AMR wanted!
Latest NewsThe start-up competition @AMR conference supported by INCATE has started. Early-stage ventures fighting drug resistant bacterial infections in the therapeutics or diagnostics area interested to be on stage are invited to apply now!
Quell raises US$156m for Treg cell therapy programme
Latest NewsQuell Therapeutics has raised a whopping US$156m from a prestigious investor group in an oversubscribed Series B financing. With the funds, the British biotech wants to hasten its CAR-Treg cell therapy candidate on its way to the clinic.